Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2018
Cargando información sobre las referencias
The purpose of this study was to evaluate the efficacy of eltrombopag for poor graft function (PGF) on overall hematologic response (partial and complete), as determined by platelet, hemoglobin and neutrophil counts by 16 weeks after the initiation of eltrombopag in patients with poor graft function after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Epistemonikos ID: 276cbd8bf91ec3a3cc0487c07abc62b6655c8281
First added on: May 21, 2024